Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain? Three Motley Fool contributors think they've found magnificent stocks that could double or more by 2030. Here's why they picked CRISPR Therapeutics ...
motleyfoolusx:llyusx:vktxusx:crsp
Shares of Swiss pharmaceuticals giant Roche Holdings (OTC: RHHBY) stock popped 2.5% in early trading Thursday before giving back about half of its gains. Roche announced this morning that the U.S. Food and Drug Administration has awarded the "Breakthrough Device Designation" to its new Elecsys pTau217 ...
motleyfoolusx:lly
As two of the most-watched and fastest-growing big pharma companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) already have upwardly mobile stock prices. And now, there's yet another piece of news that could presage even more growth over the long term. Let's explore this new development. Novo ...
motleyfoolusx:llyusx:nvo
The battle for leadership in the anti-obesity drug market is heating up. Eli Lilly (NYSE: LLY) and Novo Nordisk are the two undisputed frontrunners, but many other drugmakers are looking to challenge the status quo. Novo Nordisk's Wegovy, first approved in the U.S. in 2021, has been growing its sales ...
motleyfoolusx:lly
Investors were taking a healthy spoonful of the medicine that is Eli Lilly (NYSE: LLY) stock on Hump Day. They traded the company's shares up by nearly 2% on an analyst's recommendation upgrade. That figure was well above the scant (0.1%) gain posted by the S&P 500 index that day. The upgrade came from ...
motleyfoolusx:lly
Bear markets come and go, but history has taught investors time and time again that bull markets not only tend to outlast these periods, but eventually drive stocks higher than before the downturn hit. Both bull and bear markets can present opportunities for the long-term investor who is focusing on ...
motleyfoolusx:lly
The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them. Three Motley Fool contributors believe they've identified three stocks that fit the bill. Here's why they think CRISPR Therapeutics (NASDAQ: CRSP), Eli Lilly (NYSE: LLY), ...
motleyfoolusx:llyusx:vrtxusx:crsp
Getting to a $1 trillion market cap is a huge achievement for a company, as only the best of the best can join that club. Not only do companies need to generate strong results, but investors also need to be optimistic about their future growth for their valuations to reach such highs. Two stocks that ...
motleyfoolusx:lly
Are stock splits back in style? About two years ago, a number of high-profile corporations made such moves after their shares rose to unwieldy levels. Now, Chipotle, one of the leading fast-casual restaurant chains, is on the verge of conducting a 50-for-1 stock split. It was arguably about time -- Chipotle ...
motleyfoolusx:regnusx:lly
The pharmaceutical industry is scrambling for breakthroughs in weight loss treatment. Demand for medications such as Ozempic, Wegovy, Mounjaro, and Zepbound is rising. All of these diabetes and obesity treatments are developed by just two companies: Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY). ...
motleyfoolusx:llyusx:nvo
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are the top two healthcare stocks in the world based on market cap. Their diabetes and weight loss medications are a big reason these have been among the best healthcare investments to own over the past few years. Today, Eli Lilly is the larger of the ...
motleyfoolusx:llyusx:nvo
As great of an investment as Eli Lilly (NYSE: LLY) is during the age of Zepbound, its newest and hottest weight-loss drug, there are many other magnificent opportunities out there right now, and it'd be a disservice to your portfolio to ignore them entirely. Take Iovance Biotherapeutics (NASDAQ: IOVA), ...
motleyfoolusx:llyusx:iova
Investors can be procrastinators. It's easy to get caught up in analyzing stocks so much that people put off buying them. But that doesn't have to be the case. Three Motley Fool contributors have identified unstoppable stocks they think you can buy now without any hesitation. Here's why they chose Eli ...
motleyfoolusx:llyusx:vrtxusx:nvo
It's hard to overstate just how successful the expansions of new diabetes treatments into the weight management arena have been for the companies that sell them. In one striking example, the market capitalization of Novo Nordisk (NYSE: NVO), formerly a relatively obscure drugmaker that until recently ...
motleyfoolusx:amznusx:llyusx:nvo
When a company's big plans go awry, it's always worth reconsidering the merits of an investment. On March 8, regulators at the Food and Drug Administration (FDA) gave Eli Lilly (NYSE: LLY) an unwelcome surprise. Rather than granting approval to commercialize the company's Alzheimer's disease drug donanemab ...
motleyfoolusx:lly
Eli Lilly (NYSE: LLY) has a market capitalization of around $700 billion after soaring 130% over the past 12 months. Investors have become bullish on the company's long-term prospects, particularly with regulators recently approving Zepbound, a weight-loss drug from Eli Lilly that has shown in clinical ...
motleyfoolusx:lly
Over the past year, Eli Lilly (NYSE: LLY) has impressed investors on almost every front. Financial results have been excellent, clinical progress has been solid, and its stock has crushed the broader market. If there is one area where Eli Lilly hasn't been close to perfect, though, it's with its planned ...
motleyfoolusx:lly
It's difficult to find a group of companies that have performed better than the "Magnificent Seven" in the past decade. This clique includes the following market leaders: Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. These companies have achieved outsize returns partly due to ...
motleyfoolusx:nflxusx:lly
Eli Lilly (NYSE: LLY) stock was on quite a roll this young year, but a new development shifted that momentum on Friday. The shares fell as much as 3.2% in price on Friday afternoon, following the news that a top regulator is delaying a decision on one of the company's most important drug candidates. ...
motleyfoolusx:lly
Two of the biggest names in the pharmaceutical industry right now are Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). Each company is at the forefront of the red-hot weight-loss market due to their innovative roster of diabetes medications. Both companies develop glucagon-like peptide-1 (GLP-1) drugs, ...
motleyfoolusx:llyusx:nvo
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are two of the hottest pharmaceutical stocks of the past three years. Both companies have marked returns far in excess of the market's, thanks to popular demand for their freshly launched medications that treat obesity as well as type 2 diabetes. Both ...
motleyfoolusx:llyusx:nvo
Comparing Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) might initially seem odd. The two drugmakers don't seem to have much in common. Eli Lilly is more than 50 times the size of Viking by market cap and boasts a long list of approved medicines and an impressive track record of success. ...
motleyfoolusx:llyusx:vktx
You can find growth stocks in every sector. With healthcare making up nearly one-fifth of the U.S. economy, it's a great place to look. Three Motley Fool contributors have identified what they think are magnificent growth stocks to buy in March -- and all of them are in the healthcare sector. Here's ...
motleyfoolusx:mrnausx:llyusx:vrtx
Eli Lilly (NYSE: LLY) is the largest healthcare company in the world by market capitalization. With dividends reinvested, the company's stock is up an eye-popping 1,530% over the past 10 years. But over the last year, in particular, Lilly's stock has enjoyed an unprecedented run, fueled by interest in ...
motleyfoolusx:lly
